drugset
drugset / Trial / NCT06512467

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

NCT06512467 ↗

Phase 2 Not yet recruiting 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.

Timeline

Start
2024-07-30
Primary completion
2026-07-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 200 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

hepatocellular carcinoma